Skip to content

The effect of powder Maa al-jobon-e aftimouni on glucose and glycosylated hemoglobin levels

The effect of powder Maa al-jobon-e aftimouni on glucose and glycosylated hemoglobin levels in patients with type 2 diabetes referred to Arak outpatient diabetes clinic in 98

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190524043687N1
Enrollment
104
Registered
2020-02-25
Start date
2020-04-08
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group 1, who in addition to the usual oral medications of diabetes, Take 3 tablespoons of powder Maa al-jobon-e aftimouni daily in 250 ml of warm water fasting one hour

Sponsors

Arak University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Type 2 diabetes mellitus and full dose oral medication based on doctor prescription Age range 30 to 60 years Signing the consent form Fasting blood glucose with a drug or diet between 150 and 250 mg / dl, at least 2 months before the start of the study, with a mean fasting blood glucose between 150 and 250 and HbA1c between 6.5 and 9.5% No smoking and alcohol as well as no other herbal supplements No chronic and various complications of diabetes based on history, examination, and paraclinical findings. And not having any chronic or advanced disease Normal mental status and no mental disorder that impedes compliance with the study protocol Insensitivity to milk and its components lack of Pregnancy and lactation; And women who decide to get pregnant

Exclusion criteria

Exclusion criteria: Patient hospitalization during project implementation Non-compliance with the study protocol (no powder consumption less than 70%) Causes illness and complications that prevent them from continuing to study Changes in the routine treatment of the patient according to the physician (changes in the type and dosage of drugs used, insulin therapy)

Design outcomes

Primary

MeasureTime frame
Fasting blood sugar. Timepoint: Before intervention, 8 weeks after intervention. Method of measurement: Blood test in mg / dl.;Glycosylated hemoglobin. Timepoint: Before intervention, 8 weeks after intervention. Method of measurement: Blood test.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Safdari

Arak University of Medical Sciences

asafdari.nu@gmail.com+98 86 3417 3505

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026